JP2017515910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515910A5 JP2017515910A5 JP2017512462A JP2017512462A JP2017515910A5 JP 2017515910 A5 JP2017515910 A5 JP 2017515910A5 JP 2017512462 A JP2017512462 A JP 2017512462A JP 2017512462 A JP2017512462 A JP 2017512462A JP 2017515910 A5 JP2017515910 A5 JP 2017515910A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- inhibitors
- nfκb
- mek
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92455 | 2014-05-16 | ||
| LU92455 | 2014-05-16 | ||
| PCT/IB2015/053644 WO2015173788A1 (en) | 2014-05-16 | 2015-05-18 | Novel anti-infective strategy against influenza virus and s. aureus coinfections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218254A Division JP2021059592A (ja) | 2014-05-16 | 2020-12-28 | インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515910A JP2017515910A (ja) | 2017-06-15 |
| JP2017515910A5 true JP2017515910A5 (enExample) | 2018-06-28 |
| JP6818676B2 JP6818676B2 (ja) | 2021-01-20 |
Family
ID=50980349
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512462A Expired - Fee Related JP6818676B2 (ja) | 2014-05-16 | 2015-05-18 | インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略 |
| JP2020218254A Pending JP2021059592A (ja) | 2014-05-16 | 2020-12-28 | インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218254A Pending JP2021059592A (ja) | 2014-05-16 | 2020-12-28 | インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10456440B2 (enExample) |
| EP (2) | EP3142658B1 (enExample) |
| JP (2) | JP6818676B2 (enExample) |
| KR (1) | KR102405136B1 (enExample) |
| CN (3) | CN116942832A (enExample) |
| AU (3) | AU2015260765B2 (enExample) |
| BR (1) | BR112016026556A8 (enExample) |
| CA (1) | CA2949004A1 (enExample) |
| EA (1) | EA039897B1 (enExample) |
| WO (1) | WO2015173788A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015173788A1 (en) | 2014-05-16 | 2015-11-19 | Westfaelische Wilhelms-Universitaet Muenster | Novel anti-infective strategy against influenza virus and s. aureus coinfections |
| CA3016119A1 (en) * | 2016-03-01 | 2017-09-08 | Emerging Viral Therapeutics (HK) Limited | Compositions and methods for treatment of influenza virus |
| GB201611712D0 (en) | 2016-07-02 | 2016-08-17 | Hvivo Services Ltd | Methods and compounds for the treatment or prevention of severe or persistent influenza |
| KR20190064562A (ko) * | 2016-07-08 | 2019-06-10 | 메타스타트, 아이앤씨. | Mena 단백질 이소형 키나제를 표적화하는 항암 요법을 위한 방법 및 조성물 |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| ES2883639T3 (es) * | 2017-10-17 | 2021-12-09 | Atriva Therapeutics Gmbh | Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas |
| GB201718285D0 (en) * | 2017-11-03 | 2017-12-20 | Discuva Ltd | Antibacterial Compounds |
| GB201721793D0 (en) * | 2017-12-22 | 2018-02-07 | Hvivo Services Ltd | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza |
| EP3873458A4 (en) * | 2018-11-02 | 2022-07-06 | University of Maryland, Baltimore | TYPE 3 SECRETION SYSTEM INHIBITORS AND ANTIBIOTIC THERAPY |
| CN110063954B (zh) * | 2019-04-10 | 2021-08-06 | 华中农业大学 | Fhpi在制备治疗猫传染性腹膜炎药物中的应用 |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| CN110292593A (zh) * | 2019-08-05 | 2019-10-01 | 广州呼吸健康研究院 | 厚朴在制备抗流感药物上的应用 |
| KR20220074869A (ko) | 2019-08-27 | 2022-06-03 | 아트리바 테라퓨틱스 게엠베하 | Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합 |
| KR20220079573A (ko) | 2019-10-08 | 2022-06-13 | 아트리바 테라퓨틱스 게엠베하 | 한타바이러스 감염의 치료를 위한 mek 억제제 |
| CN110859845B (zh) * | 2019-12-10 | 2021-02-02 | 南京医科大学 | 丹参酮类化合物的应用 |
| EP4085054B1 (en) * | 2020-01-02 | 2025-02-19 | Helmholtz-Zentrum für Infektionsforschung GmbH | New pqsr inverse agonists |
| WO2021142144A1 (en) | 2020-01-10 | 2021-07-15 | Immuneering Corporation | Mek inhibitors and therapeutic uses thereof |
| MX2022013196A (es) * | 2020-04-22 | 2022-11-14 | Atriva Therapeutics Gmbh | Inhibidores de rock para usarse en el tratamiento o prevencion del edema pulmonar. |
| KR102641463B1 (ko) * | 2020-08-18 | 2024-02-27 | 한국생명공학연구원 | 바이러스 감염질환의 예방 또는 치료를 위한 화합물, 이를 포함하는 조성물 및 이의 용도 |
| CN112552189A (zh) * | 2020-11-10 | 2021-03-26 | 中国海洋大学 | 一种盐酸金刚烷胺与白藜芦醇的药物共晶及其制备方法 |
| WO2023084489A1 (en) * | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| CN116159140B (zh) * | 2021-11-25 | 2025-07-25 | 中国科学院上海免疫与感染研究所 | Mapk通路抑制剂在抗病原体感染中的应用 |
| WO2023170187A1 (en) * | 2022-03-09 | 2023-09-14 | Technische Universität München | INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX |
| CN115644134B (zh) * | 2022-10-31 | 2025-10-10 | 中国人民解放军军事科学院军事医学研究院 | 一种布鲁氏菌-甲型流感病毒共感染小鼠模型及其构建方法和应用 |
| KR20240087518A (ko) | 2022-12-01 | 2024-06-19 | 서울여자대학교 산학협력단 | 카페산을 포함하는 식물바이러스 방제용 조성물 및 이를 이용한 식물바이러스 방제 방법 |
| CN118490680B (zh) * | 2023-06-20 | 2025-02-11 | 吉林省西点药业科技发展股份有限公司 | 瑞香素在制备治疗病毒性肺炎的药物中的应用 |
| CN116531389B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合雷公藤红素的应用及药物组合物 |
| CN117105810B (zh) * | 2023-10-23 | 2024-02-09 | 中国农业大学 | 一种具有广谱抗菌活性的化合物及其抗菌组合物 |
| CN119925338A (zh) * | 2025-02-10 | 2025-05-06 | 广州医科大学附属妇女儿童医疗中心 | Bay 11-7085在防治肺炎中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL191111B1 (pl) | 1997-04-24 | 2006-03-31 | Ortho Mcneil Pharm Inc | Podstawione imidazole, sposób ich wytwarzania, kompozycje zawierające podstawione imidazole oraz ich zastosowanie |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| EP0994858A1 (en) | 1997-06-30 | 2000-04-26 | Ortho-McNeil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| PL340412A1 (en) | 1997-10-20 | 2001-01-29 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| CA2321559A1 (en) | 1998-02-26 | 1999-09-02 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrrolobenzimidazoles for treating inflammatory diseases |
| US6448257B1 (en) | 1998-05-22 | 2002-09-10 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| BR9913654A (pt) | 1998-08-28 | 2001-11-27 | Scios Inc | Inibidores de p-38alfa quinase |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| US6509361B1 (en) | 1999-05-12 | 2003-01-21 | Pharmacia Corporation | 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors |
| EP1353905B1 (en) | 2000-11-20 | 2007-01-10 | Scios Inc. | Piperidine/piperazine-type inhibitors of p38 kinase |
| AU2002303132A1 (en) | 2001-03-16 | 2002-10-03 | Tyler Curiel | Inhibition of toxoplasma gondii) replication by pyridinylimidazoles |
| US7345078B2 (en) * | 2002-05-31 | 2008-03-18 | The Board Of Trustees Of Michigan State University | NF-κB inhibitors and uses thereof |
| JP2007055983A (ja) * | 2005-08-26 | 2007-03-08 | Tokyo Univ Of Science | 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤 |
| DE102008004386A1 (de) * | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen |
| EP2903649A1 (en) | 2012-10-08 | 2015-08-12 | Westfälische Wilhelms-Universität Münster | Mek inhibitors in the treatment of virus diseases |
| WO2015173788A1 (en) | 2014-05-16 | 2015-11-19 | Westfaelische Wilhelms-Universitaet Muenster | Novel anti-infective strategy against influenza virus and s. aureus coinfections |
-
2015
- 2015-05-18 WO PCT/IB2015/053644 patent/WO2015173788A1/en not_active Ceased
- 2015-05-18 CA CA2949004A patent/CA2949004A1/en active Pending
- 2015-05-18 CN CN202310240041.7A patent/CN116942832A/zh active Pending
- 2015-05-18 AU AU2015260765A patent/AU2015260765B2/en not_active Ceased
- 2015-05-18 BR BR112016026556A patent/BR112016026556A8/pt not_active Application Discontinuation
- 2015-05-18 EP EP15726345.0A patent/EP3142658B1/en active Active
- 2015-05-18 KR KR1020167035245A patent/KR102405136B1/ko active Active
- 2015-05-18 CN CN201580038887.6A patent/CN107073123A/zh not_active Withdrawn
- 2015-05-18 CN CN202110506866.XA patent/CN113398271A/zh active Pending
- 2015-05-18 EA EA201692303A patent/EA039897B1/ru unknown
- 2015-05-18 US US15/310,836 patent/US10456440B2/en active Active
- 2015-05-18 JP JP2017512462A patent/JP6818676B2/ja not_active Expired - Fee Related
- 2015-05-18 EP EP20151682.0A patent/EP3708156A1/en not_active Withdrawn
-
2019
- 2019-09-16 US US16/571,550 patent/US11135263B2/en not_active Expired - Fee Related
-
2020
- 2020-10-13 AU AU2020256326A patent/AU2020256326B2/en not_active Ceased
- 2020-12-28 JP JP2020218254A patent/JP2021059592A/ja active Pending
-
2021
- 2021-10-01 US US17/492,088 patent/US20220096590A1/en not_active Abandoned
-
2022
- 2022-11-10 AU AU2022268364A patent/AU2022268364A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515910A5 (enExample) | ||
| AU2020256326B2 (en) | Novel Anti-Infective Strategy Against Influenza Virus And S.aureus Coinfections | |
| Zhu et al. | Baicalin inhibits autophagy induced by influenza A virus H3N2 | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112012028091A2 (pt) | composições farmacêuticas compreendendo pioglitazona e linagliptina | |
| BR112018002304A8 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112017027798A2 (pt) | compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112021018335A2 (pt) | Derivados de benzodiazepina como inibidores de rsv | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BR112015009504A2 (pt) | inibidores de rock | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
| BR112018008076A2 (pt) | derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos | |
| BR112021025236A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina | |
| BR112012029259A8 (pt) | tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos | |
| BR112016029619A8 (pt) | Compostos da classe de fluoroquinolonas, composição farmacêutica e medicamento compreendendo tais compostos e usos de tais compostos | |
| CO6660504A2 (es) | Agente terapeutico de liberacion sostenida para la hipertensión y la disfunción renal | |
| BR112013029790A2 (pt) | composição farmacêutica compreendendo cetoprofeno | |
| CY1113544T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος |